钠-葡萄糖协同转运蛋白2抑制剂与心力衰竭的临床研究进展

Sodium-glucose Cotransporter 2 Inhibitor and Heart Failure

糖尿病是心血管事件的独立危险因素,心血管疾病合并糖尿病时增加患者死亡风险。新型降糖药钠-葡萄糖协同转运蛋白2抑制剂被证实可显著降低糖尿病患者的心血管死亡率和心力衰竭住院率,机制可能与降低心脏负荷、改善心脏能量代谢和改善心肌重构等相关。现阐述钠-葡萄糖协同转运蛋白2抑制剂在心力衰竭防治方面最新的研究进展,为心力衰竭的治疗提供新思路。

Diabetes is an independent risk factor for cardiovascular events,and cardiovascular disease with diabetes increases the risk of death.The novel sodium-glucose cotransporter 2 inhibitor has been shown to significantly reduce the cardiovascular mortality and hospitalization rate of heart failure in diabetic patients,and the mechanism may be related to the reduction of cardiac load,improvement of cardiac energy metabolism and myocardial remodeling.This article reviews the latest research progress of sodium-glucose cotransporter 2 inhibitors in the prevention and treatment of heart failure,providing a new idea for the treatment of heart failure.